Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Metabolomics Services Companies

Metabolomics services companies provide comprehensive solutions for the analysis and interpretation of metabolites within biological systems. These services typically involve the identification, quantification, and profiling of small molecules to gain insights into various biological processes, disease mechanisms, and drug responses.

Metabolomics Services Key CompaniesLatest Metabolomics services Companies Update

Sep 2023 The launch of the new Biological Stress Discovery Panel has been announced by Metabolon, Inc., a leader in offering metabolomics solutions for a wide range of research, diagnostic, clinical development, and medical applications. The Biological Stress Discovery Panel, a component of the Metabolon Discover portfolio of metabolomics services, includes 114 metabolites strongly associated with chronic stress and sheds light on several biological stress pathways, such as inflammation, injury, circulation, and oxidative stress. The panel also looks at additional molecules that signal signatures that can reveal the presence and activity of stressors and gauge a person's ability to handle stress.


Oct 2023 To facilitate biologics production at the facility, Thermo Fisher Scientific has increased the capacity for production at its St. Louis, Missouri, location. The US-based biotechnology and healthcare products company has recently expanded its biologic manufacturing capabilities to meet the rising demand for these treatments. A biologics production facility in Lengnau, Switzerland, was leased by Thermo Fisher in June. A manufacturing facility for cell therapy, a biologic product, was added to the company's expanding network in March in San Francisco (US). Numerous organizations and businesses have made investments of millions in constructing biologics production facilities in response to the rising demand for these treatments. Up to four Thermo Scientific DynaDrive single-use bioreactors (SUB), each with a processing capacity of 5,000L will be added to the St. Louis plant expansion. The facility will support manufacturing biological treatments for various illnesses, including cancer, autoimmune disorders, and rare genetic abnormalities.List of Metabolomics services Key companies in the market



  • Agilent Technologies, Inc. (U.S.)

  • Waters (U.S.)

  • Bruker (U.S.)

  • TMIC (CANADA)

  • Thermo Fisher Scientific (U.S.),

  • Biocrates Life Sciences AG (AUSTRIA)

  • Creative Proteomics (U.S.)

  • Human Metabolome Technologies America Inc (JAPAN)

  • Shimazdu Corporation (Japan)

  • Metabolon, INC (U.S.)

Metabolomics Services Market Overview


Metabolomics Services Market size was valued USD 2.02 Billion in 2021 and is expected to reach USD 6.36 billion by 2030 at 11.92% CAGR during the forecast period 2022-2030. Metabolomics can be described as examining and analyzing biochemical processes relating to intermediates and byproducts of metabolic activities. These products are known as metabolomes, which reproduce all metabolites involved in numerous reactions in an organism, counting secondary metabolites, signaling molecules, hormones, and metabolic intermediates. Its application in toxicology, environmental analysis, disease research, agriculture, biofuel development & nutrition is estimated to be a broad scope for developing the metabolomics services market size in the coming period.


COVID-19 Analysis


The cold chain and pharmaceutical industries were impelled to revolutionize throughout vaccine development, including the production of temperature-controlled packages that met the revised deep-frozen vaccine storage requirements and amplified demand for existing products. The industry soared to the challenge posed by COVID, working by employing unique ways to bolster the metabolomics services market share. The metabolome is exceptionally dynamic, and metabolism shifts often lead to clinical phenotype changes. The use of metabolomics is being leveraged to shape our understanding of COVID-19, which could play a vital role. The fruitful cases for biomarker study in pneumonia, sepsis, and comorbidities related to many COVID-19 infections indicate the possibility of metabolomics to bring about an adapted health care strategy for Covid-19, delivering safe and effective treatments to patients.


Market Dynamics


Drivers


Growing Prevalence Of Cancer


The surge in cancer cases globally in different body areas is predicted to motivate the metabolomics services market size in the upcoming period.


Technological Advancements In Instrumentation


The breakthroughs in the instruments used for metabolomics related studies is estimated to enhance the global market considerably in the forecast period.


Increasing Application Of Metabolomics


The use of metabolomics in various studies for diverse ailments is predicted to spur the growth of the Metabolomics Services Market.


Opportunities


Expansion In Developing Countries


The development of emerging economies is estimated to shape the Metabolomics Services Market considerably in the forecast period. With increased funding for businesses' research and growth, it is predicted to transform the countries' metabolomics market.


Challenges


High Cost Of Instruments


The raised costs associated with using the metabolomics tools and services are estimated to stagnate the growth of the Metabolomics Services Market.


Government Policies And Regulations


The strict regulations related to healthcare-related businesses are estimated to create fresh expansion opportunities in the forecast period.


Segment Overview


By Product And Service


The mass spectrometry segment is estimated to have a majority share of the global market, with metabolomics bioinformatics services coming in second through the forecast period.


By Application


The biomedical & pharmaceutical segment accounted for the largest market share in 2021 and is estimated to control the upcoming period's Metabolomics Services Market share.


Regional Analysis


Americas Regional Market To Lead With Vast Expertise


The Americas regional market is expected to hold the market's principal share. This is due to the swelling patient population base that is suffering from cancer, and cardiovascular diseases are predicted to boost the Metabolomics Services Market growth in this region.


Presence Of Strong Contenders To Spur European Region


The European market holds the next major position in the metabolomics services market. Numerous companies in the region provide metabolomics services, which is predicted to drive the region's growth in the metabolomics services market.


APAC To Be Incentivized By Huge Patient Base


The Asia Pacific regional metabolomics market is estimated to be the fastest mounting region due to many patient populations suffering from chronic disease and collective demand for therapy.  


Competitive Landscape


The prolific companies in the Metabolomics Services Market are



  • Agilent Technologies, Inc. (U.S.),

  • Waters (U.S.),

  • Bruker (U.S.),

  • TMIC (CANADA),

  • Thermo Fisher Scientific (U.S.),

  • Biocrates Life Sciences AG (AUSTRIA),

  • Creative Proteomics (U.S.),

  • Human Metabolome Technologies America Inc (JAPAN),

  • Shimazdu Corporation (Japan),

  • Metabolon, INC (U.S.)


Recent Developments


Jan 2021 OWL and BIOSFER, biotech players, have arrived at a strategic partnership to reinforce R&D in developing diagnostic methods and personalized medicine use metabolomics. The agreement permits both groups to identify prospects, produce detailed proposals, and find the most suitable backing to safeguard these projects' victory and make them advantageous for society and the biotechnology industry. OWL and BIOSFER have widespread knowledge of metabolomic technology for application in various areas, such as increasing new biomarkers to create diagnostic products or encourage advanced platforms for studies and clinical tests in the pharmaceutical industry. 


Jan 2021 numares A.G., a leading metabolomics diagnostics company, and Bruker Corporation have decided to cooperate to bring novel diagnostics tests employing NMR to the laboratory market unmet medical requirements. The tests are created on the automated measurement of metabolites via artificial intelligence and a strong magnetic field. The platform is advertised under the numares brand AXINON. This partnership will support the current transition of AXINON  platform from research into routine clinical use and makes it accessible to all patients as a reasonably priced, day-to-day diagnostic standard.


Aug 2020 Metabolon, Inc., the global leader in metabolomics, has entered into a multi-year association with Merck KGaA, Germany, a top science and technology company. Merck KGaA, Germany, runs its biopharmaceuticals business in the U.S. and Canada as EMD Serono. Metabolon will back clinical & translational research developments through therapeutic areas as an exploratory metabolomics associate. Through this partnership, Metabolon will achieve worldwide metabolomics and deliver top biological interpretation and examination of the results to shed light on biomarkers and biochemical pathways detected to progress both the rapidity and yield of Merck KGaA's drug development pipeline.


July 2020 ReviveMed has announced that they are pursuing an assessment analysis with Bristol Myers Squibb. This analysis will use ReviveMed's artificial intelligence (A.I.) platform to understand the mechanisms of resistance and response to immunotherapies in cancer patients. ReviveMed has built one of the most comprehensive databanks about metabolites and their relation with other molecules. Their exclusive A.I. algorithm utilizes this database to classify a large number of metabolites for individual patients quickly and at a low cost. ReviveMed's AI-driven platform interprets this large number of data to discover novel disease mechanisms and molecules for drug discovery purposes.


Segment Overview


By Product And Service



  • Chromatography

  • Metabolomics Bioinformatics Services

  • Mass Spectrometry


By Application




  • Biomedical and Pharmaceutical




  • Agriculture




  • Food



Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.